Once the complication has occurred, most authors advocate the early withdrawal of the implanted Ozurdex device by means of crystalline phacoemulsification and then repositioning it in the vitreous body. However, as long as there are no signs of inflammation in the anterior pole, the IOP is within normal limits, the device does not affect the visual axis and there is no cataract development, we can evaluate the potential therapeutic effect of Ozurdex in this non-indicated, abnormal location.

No abstract

No abstract

No abstract

No abstract